NASDAQ:ALKS Alkermes - ALKS Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Alkermes plc Please log in to your account or sign up in order to add this asset to your watchlist. $27.92 +0.63 (+2.31%) (As of 03/29/2023 12:00 AM ET) Add Compare Share Share Today's Range$27.28▼$27.9750-Day Range$25.75▼$29.0252-Week Range$21.75▼$32.79Volume1.13 million shsAverage Volume1.26 million shsMarket Capitalization$4.59 billionP/E RatioN/ADividend YieldN/APrice Target$30.63 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Alkermes MarketRank™ ForecastAnalyst RatingHold2.43 Rating ScoreUpside/Downside9.7% Upside$30.63 Price TargetShort InterestBearish5.76% of Shares Sold ShortDividend StrengthN/ASustainability-1.22Upright™ Environmental ScoreNews Sentiment0.34Based on 8 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.51) to $1.02 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.39 out of 5 starsMedical Sector855th out of 999 stocksPharmaceutical Preparations Industry417th out of 489 stocks 1.2 Analyst's Opinion Consensus RatingAlkermes has received a consensus rating of Hold. The company's average rating score is 2.43, and is based on 3 buy ratings, 4 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $30.63, Alkermes has a forecasted upside of 9.7% from its current price of $27.92.Amount of Analyst CoverageAlkermes has only been the subject of 1 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted5.76% of the outstanding shares of Alkermes have been sold short.Short Interest Ratio / Days to CoverAlkermes has a short interest ratio ("days to cover") of 7.6.Change versus previous monthShort interest in Alkermes has recently increased by 5.46%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldAlkermes does not currently pay a dividend.Dividend GrowthAlkermes does not have a long track record of dividend growth. Previous Next 4.5 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreAlkermes has received a 69.44% net impact score from Upright. The largest positive contribution comes from its "Mental diseases" impact, which is mostly driven by its "Antipsychotics", "Naltrexone", and "Clinical research services for mental health" products. See details.Environmental SustainabilityThe Environmental Impact score for Alkermes is -1.22. Previous Next 1.9 News and Social Media Coverage News SentimentAlkermes has a news sentiment score of 0.34. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for Alkermes this week, compared to 5 articles on an average week.Search InterestOnly 1 people have searched for ALKS on MarketBeat in the last 30 days. This is a decrease of -90% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Alkermes to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Alkermes insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.76% of the stock of Alkermes is held by insiders.Percentage Held by Institutions96.15% of the stock of Alkermes is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Alkermes are expected to grow in the coming year, from ($0.51) to $1.02 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Alkermes is -29.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Alkermes is -29.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAlkermes has a P/B Ratio of 4.40. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Alkermes (NASDAQ:ALKS) StockAlkermes Plc is a global biopharmaceutical company, which engages in the business of developing, manufacturing, and commercializing medicines designed to address unmet medical needs of patients in major therapeutic areas such as alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of product candidates in development for neurological disorders and cancer. Its proprietary products include ARISTADA, ARISTADA INITIO, LYBALVI, and VIVITROL. The company was founded in 1987 and is headquartered in Dublin, Ireland.Read More Receive ALKS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Alkermes and its competitors with MarketBeat's FREE daily newsletter. Email Address ALKS Stock News HeadlinesMarch 27, 2023 | americanbankingnews.comAlkermes (NASDAQ:ALKS) Lifted to "Strong-Buy" at StockNews.comMarch 23, 2023 | finance.yahoo.comJournal of Clinical Psychiatry Publishes Data from Alkermes' ENLIGHTEN-Early Study of LYBALVI® (olanzapine and samidorphan) in Young Adults Early in Their IllnessMarch 29, 2023 | Investor Place Media (Ad)The "King Of Quants" sees 10X potential...Eric Fry believes he just discovered America's next "Wealth Supercluster" and it's forming in the place you'd least expect. Investors are already flocking there for a chance at 1,000%+ returns. Here's how you could join them before it's too late...March 15, 2023 | finance.yahoo.comAlkermes (ALKS) Stock Up 15% in Six Months: Here's WhyMarch 15, 2023 | finance.yahoo.comAlkermes to Participate in the Stifel 2023 CNS DaysMarch 11, 2023 | finance.yahoo.comA Alkermes plc (NASDAQ:ALKS) insider increased their holdings by 63% last yearFebruary 18, 2023 | finance.yahoo.comAlkermes Full Year 2022 Earnings: Beats ExpectationsFebruary 16, 2023 | finance.yahoo.comAlkermes plc Reports Financial Results for the Fourth Quarter and Year Ended Dec. 31, 2022 and Provides Financial Expectations for 2023March 29, 2023 | Investor Place Media (Ad)The "King Of Quants" sees 10X potential...Eric Fry believes he just discovered America's next "Wealth Supercluster" and it's forming in the place you'd least expect. Investors are already flocking there for a chance at 1,000%+ returns. Here's how you could join them before it's too late...February 9, 2023 | finance.yahoo.comAlkermes to Report Fourth Quarter and Year-End Financial Results on Feb. 16, 2023February 3, 2023 | finance.yahoo.comIs There An Opportunity With Alkermes plc's (NASDAQ:ALKS) 45% Undervaluation?January 17, 2023 | finance.yahoo.comAlkermes Awarded Innovation Passport Designation by the MHRA (UK) for Nemvaleukin Alfa for the Treatment of Mucosal MelanomaJanuary 14, 2023 | seekingalpha.comAlkermes (ALKS) Presents at the 41st Annual J.P. Morgan Healthcare Conference -- SlideshowDecember 28, 2022 | finance.yahoo.comAlkermes to Present at the 41st Annual J.P. Morgan Healthcare ConferenceDecember 26, 2022 | thestreet.comAlkermes Testing Schizophrenia DrugDecember 26, 2022 | thestreet.comAlkermes Depression Drug Failure Crimps Future Growth OutlookNovember 30, 2022 | finance.yahoo.comAlkermes to Participate in the BofA Securities 2022 Biotech SMID Cap ConferenceNovember 22, 2022 | finance.yahoo.comAlkermes to Participate in the 5th Annual Evercore ISI HealthCONx ConferenceNovember 8, 2022 | finance.yahoo.comAlkermes to Participate in the Stifel Healthcare ConferenceNovember 7, 2022 | finance.yahoo.comAlkermes Announces Recipients of 2022 Alkermes Inspiration Grants(R) ProgramOctober 27, 2022 | finance.yahoo.comAlkermes Announces Recipients of 2022 Alkermes Inspiration Grants® ProgramOctober 26, 2022 | finance.yahoo.comAlkermes to Report Third Quarter Financial Results on Nov. 2, 2022October 17, 2022 | seekingalpha.comACOR stock gains after winning $16.5M from Alkermes in arbitration case (NASDAQ:ACOR) - Seeking AlphaOctober 17, 2022 | streetinsider.comAcorda Therapeutics (ACOR) Awarded $16.5M in Arbitration Case with Alkermes (ALKS) - StreetInsider.comOctober 17, 2022 | nasdaq.comAcorda Announces $16.5 Mln Award And Royalty/Supply Relief In AMPYRA Arbitration Case With Alkermes - NasdaqOctober 16, 2022 | businesswire.comAcorda Therapeutics Announces $16.5M Award and Royalty/Supply Relief in AMPYRA® Arbitration Case - Business WireOctober 14, 2022 | wnewsj.comBridge to past & future: Community celebrates 150 years of Champion Bridge Co. - Wilmington News Journal, OHSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive ALKS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Alkermes and its competitors with MarketBeat's FREE daily newsletter. Email Address ALKS Company Calendar Last Earnings2/16/2023Today3/29/2023Next Earnings (Estimated)4/26/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:ALKS CUSIPG0176710 CIK1520262 Webwww.alkermes.com Phone(531) 772-8000Fax781-890-0524Employees2,280Year Founded1987Price Target and Rating Average Stock Price Forecast$30.63 High Stock Price Forecast$36.00 Low Stock Price Forecast$25.00 Forecasted Upside/Downside+9.7%Consensus RatingHold Rating Score (0-4)2.43 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($0.96) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-158,270,000.00 Net Margins-14.23% Pretax Margin-15.05% Return on Equity-3.32% Return on Assets-1.80% Debt Debt-to-Equity Ratio0.28 Current Ratio2.27 Quick Ratio1.91 Sales & Book Value Annual Sales$1.11 billion Price / Sales4.13 Cash Flow$0.27 per share Price / Cash Flow104.96 Book Value$6.35 per share Price / Book4.40Miscellaneous Outstanding Shares164,390,000Free Float156,564,000Market Cap$4.59 billion OptionableOptionable Beta0.60 Social Links Key ExecutivesRichard F. PopsChairman & Chief Executive OfficerBlair C. JacksonChief Operating Officer & Executive Vice PresidentIain Michael BrownChief Financial Officer & Senior Vice PresidentThomas HarveyChief Information Officer & Senior VP-ITKanchan RelwaniSenior Vice President-Medical AffairsKey CompetitorsMadrigal PharmaceuticalsNASDAQ:MDGLIonis PharmaceuticalsNASDAQ:IONSAmicus TherapeuticsNASDAQ:FOLDIronwood PharmaceuticalsNASDAQ:IRWDDynavax TechnologiesNASDAQ:DVAXView All CompetitorsInsiders & InstitutionsNeo Ivy Capital ManagementBought 3,702 shares on 3/27/2023Ownership: 0.002%Voya Investment Management LLCBought 2,257 shares on 2/28/2023Ownership: 0.135%Teachers Retirement System of The State of KentuckyBought 16,850 shares on 2/22/2023Ownership: 0.010%Macquarie Group Ltd.Sold 1,982 shares on 2/21/2023Ownership: 0.257%Auxier Asset ManagementSold 1,200 shares on 2/17/2023Ownership: 0.008%View All Insider TransactionsView All Institutional Transactions ALKS Stock - Frequently Asked Questions Should I buy or sell Alkermes stock right now? 7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Alkermes in the last twelve months. There are currently 4 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" ALKS shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ALKS, but not buy additional shares or sell existing shares. View ALKS analyst ratings or view top-rated stocks. What is Alkermes' stock price forecast for 2023? 7 Wall Street analysts have issued twelve-month price targets for Alkermes' stock. Their ALKS share price forecasts range from $25.00 to $36.00. On average, they predict the company's share price to reach $30.63 in the next twelve months. This suggests a possible upside of 10.8% from the stock's current price. View analysts price targets for ALKS or view top-rated stocks among Wall Street analysts. How have ALKS shares performed in 2023? Alkermes' stock was trading at $26.13 at the beginning of 2023. Since then, ALKS stock has increased by 5.8% and is now trading at $27.64. View the best growth stocks for 2023 here. Are investors shorting Alkermes? Alkermes saw a increase in short interest during the month of March. As of March 15th, there was short interest totaling 9,470,000 shares, an increase of 5.5% from the February 28th total of 8,980,000 shares. Based on an average daily volume of 1,240,000 shares, the short-interest ratio is presently 7.6 days. View Alkermes' Short Interest. When is Alkermes' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, April 26th 2023. View our ALKS earnings forecast. How were Alkermes' earnings last quarter? Alkermes plc (NASDAQ:ALKS) issued its earnings results on Thursday, February, 16th. The company reported $0.14 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.05 by $0.09. The company had revenue of $304.70 million for the quarter, compared to the consensus estimate of $289.80 million. Alkermes had a negative net margin of 14.23% and a negative trailing twelve-month return on equity of 3.32%. The business's revenue was down 6.1% on a year-over-year basis. During the same period last year, the firm posted $0.13 EPS. What ETFs hold Alkermes' stock? ETFs with the largest weight of Alkermes (NASDAQ:ALKS) stock in their portfolio include AdvisorShares Psychedelics ETF (PSIL), Harbor Health Care ETF (MEDI), iShares Neuroscience and Healthcare ETF (IBRN), Psyk Etf (PSYK), First Trust NYSE Arca Biotechnology Index Fund (FBT), ALPS Medical Breakthroughs ETF (SBIO), Invesco Dynamic Biotechnology & Genome ETF (PBE) and Putnam BioRevolution ETF (SYNB). What guidance has Alkermes issued on next quarter's earnings? Alkermes updated its FY 2023 earnings guidance on Monday, February, 20th. The company provided earnings per share guidance of 0-$0.23 for the period, compared to the consensus EPS estimate of $0.26. The company issued revenue guidance of $1.13 billion-$1.25 billion, compared to the consensus revenue estimate of $1.17 billion. What is Richard F. Pops' approval rating as Alkermes' CEO? 119 employees have rated Alkermes Chief Executive Officer Richard F. Pops on Glassdoor.com. Richard F. Pops has an approval rating of 84% among the company's employees. What other stocks do shareholders of Alkermes own? Based on aggregate information from My MarketBeat watchlists, some companies that other Alkermes investors own include Gilead Sciences (GILD), Netflix (NFLX), Pfizer (PFE), NVIDIA (NVDA), AbbVie (ABBV), Starbucks (SBUX), Intel (INTC), Johnson & Johnson (JNJ) and Tesla (TSLA). What is Alkermes' stock symbol? Alkermes trades on the NASDAQ under the ticker symbol "ALKS." Who are Alkermes' major shareholders? Alkermes' stock is owned by a variety of retail and institutional investors. Top institutional investors include Sarissa Capital Management LP (5.46%), Renaissance Technologies LLC (3.44%), Hardman Johnston Global Advisors LLC (3.38%), Cibc World Markets Corp (3.09%), Millennium Management LLC (2.09%) and Geode Capital Management LLC (1.85%). Insiders that own company stock include Blair Curtis Jackson, Christian Todd Nichols, Craig C Hopkinson, Craig C Hopkinson, David Joseph Gaffin, David W Anstice, Emily Peterson Alva, Iain Michael Brown, Michael J Landine, Richard F Pops, Shane Cooke and Wendy L Dixon. View institutional ownership trends. How do I buy shares of Alkermes? Shares of ALKS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Alkermes' stock price today? One share of ALKS stock can currently be purchased for approximately $27.64. How much money does Alkermes make? Alkermes (NASDAQ:ALKS) has a market capitalization of $4.54 billion and generates $1.11 billion in revenue each year. The company earns $-158,270,000.00 in net income (profit) each year or ($0.96) on an earnings per share basis. How many employees does Alkermes have? The company employs 2,280 workers across the globe. Does Alkermes have any subsidiaries? The following companies are subsidiares of Alkermes: Rodin Therapeutics.Read More How can I contact Alkermes? Alkermes' mailing address is 1 BURLINGTON ROAD CONNAUGHT HOUSE, DUBLIN L2, DUBLIN 4. The official website for the company is www.alkermes.com. The company can be reached via phone at (531) 772-8000, via email at investor_relations@alkermes.com, or via fax at 781-890-0524. This page (NASDAQ:ALKS) was last updated on 3/29/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.